Joel Mason, M.D., and Edward Saltzman, M.D.

Dr. Saltzman reports no commercial conflict of interest. In the last three years, Dr. Mason has received grant/research support from Mead-Johnson Nutritional and also served as a consultant for Mead-Johnson Nutritional.

Release Date: 03/20/1998
Termination Date: 03/20/2001

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, you should be able to:

• Discuss the increasing frequency of obesity in our society and list some of the lesser recognized co-morbidities that often accompany the condition
• Determine whether a particular individual should be classified as either overweight or obese
• Discuss the pharmacologic agents presently available for treatment of obesity, understand their safety profile, appreciate when they should be used and how their use should be integrated into weight loss programs that include other more conventional modalities of treatment.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity